Smith & Nephew (LON:SN) Price Target Raised to GBX 1,381

Smith & Nephew (LON:SN) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from GBX 1,300 ($16.33) to GBX 1,381 ($17.35) in a note issued to investors on Thursday, Digital Look reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 41.41% from the stock’s previous close.

A number of other analysts have also recently commented on SN. Barclays restated an “equal weight” rating and set a GBX 1,150 ($14.45) price target on shares of Smith & Nephew in a research note on Friday, February 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 1,500 ($18.84) price target on shares of Smith & Nephew in a research report on Friday, April 5th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,450 ($18.21) target price on shares of Smith & Nephew in a report on Thursday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of GBX 1,370.25 ($17.21).

Smith & Nephew Stock Down 0.2 %

LON:SN traded down GBX 2.40 ($0.03) on Thursday, hitting GBX 976.60 ($12.27). The stock had a trading volume of 3,690,163 shares, compared to its average volume of 343,671. The stock has a market cap of £8.54 billion, a P/E ratio of 4,069.17, a price-to-earnings-growth ratio of 0.46 and a beta of 0.51. The company has a debt-to-equity ratio of 59.11, a quick ratio of 0.84 and a current ratio of 1.77. The firm’s fifty day simple moving average is GBX 1,024.48 and its two-hundred day simple moving average is GBX 1,034.66. Smith & Nephew has a 1 year low of GBX 887 ($11.14) and a 1 year high of GBX 1,316.75 ($16.54).

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.